A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia

Current Opinion in Hematology

Volumn 18, Issue 1, 2011, Pages 1-10

  Lyman, Gary H ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Colony stimulating factors; Febrile neutropenia; Guidelines; Myeloid growth factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; MYELOID GROWTH FACTOR; PREDNISONE; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINCRISTINE;

AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NEUTROPENIA; COMPARATIVE STUDY; CONSENSUS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HUMAN; NATIONAL COMPREHENSIVE CANCER NETWORK; NATIONAL HEALTH ORGANIZATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTORS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 79851510241     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328340dc51     Document Type: Article

References (47)

1. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer p (Pubitemid 43673249)
2. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008; 6:109-118. (Pubitemid 351340522)
3. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98:2402-2409. (Pubitemid 37466655)
4. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44:2069-2076. (Pubitemid 37369646)
5. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapyinduced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23:7974-7984. (Pubitemid 46657398)
6. Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, nodepositive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23:2686-2693. (Pubitemid 46179458)
7. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90:1205-1211. (Pubitemid 28407086)
8. th ed. Philadelphia: Lippincott; 2006.
9. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21:4524-4531. (Pubitemid 46594022)
10. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22:4302-4311. (Pubitemid 41185151)
11. Lyman GH. Impact of chemotherapy dose intensity on cancer patient out-comes. J Natl Compr Canc Netw 2009; 7:99-108.
12. Shayne M, Crawford J, Dale DC, et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006; 100:255-262. (Pubitemid 44707919)
13. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110:1611-1620. (Pubitemid 47463077)
14. Shayne M, Culakova E, Wolff D, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 2009; 115:5319-5328.
15. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158-3167. (Pubitemid 47218066)
16. Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147:400-411. (Pubitemid 351664541)
17. Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 2006; 32:289-303. (Pubitemid 44502006)
18. Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23:4198-4214. (Pubitemid 46211326)
19. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23:1178-1184. (Pubitemid 46202274)
20. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3041-3050. (Pubitemid 46606283)
21. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101:3840-3848. (Pubitemid 36857855)
22. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non- Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33-38. (Pubitemid 29300131)
23. Lyman GH, Kuderer N, Agboola O, et al.Evidence-based useofcolony- stimulating factors in elderly cancer patients. Cancer Control 2003; 10:487-499. (Pubitemid 37493953)
24. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008; CD003189.
25. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12: 1416-1424.
26. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-3205. (Pubitemid 46638957)
27. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw2007; 5:188-202. (Pubitemid 46423058)
28. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42:2433-2453. (Pubitemid 44442936)
29. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw 2009; 7:64-83.
30. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12:2471-1508.
31. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-3585.
32. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3:540-555. (Pubitemid 44265428)
33. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003; 39:2264-2272. (Pubitemid 37214850)
34. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005; 3:557-571. (Pubitemid 44265429)
35. Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 2007; 5:217-228. (Pubitemid 46423060)
36. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205.
37. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodys- plastic syndrome in randomized controlled clinical trials ofcancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914-2924.
38. Fridrik MA, Hausmaninger H, Lang A, ef al. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol 2010; 89:273-282.
39. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutro penia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 2009; 45:608-617.
40. Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74:203-210.
41. Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11:172-179. (Pubitemid 351473616)
42. Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009; 12:217-225.
43. Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6- day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009; 25:401-411.
44. Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009; 31:1092-1104.
45. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98:1108-1117. (Pubitemid 44288785)
46. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051. (Pubitemid 30644129)
47. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy- induced neutropenia. Oncologist 2005; 10:427-437. (Pubitemid 40993570)